Remove 2016 Remove Immunity Remove Immunization
article thumbnail

Opinion: The window is closing to stop deadly drug-resistant fungi like Candida auris

STAT

Clinical cases have risen each year since it was first publicly reported in 2016, with 2,377 reported in 2022, and the CDC notes that based on limited information, 30–60% of those infected with C. auris infects people whose immune systems are already weakened due to other health issues. Twenty-seven states and Washington, D.C.

Immunity 254
article thumbnail

AC Immune poleaxed on Alzheimer’s study fail

pharmaphorum

Shares in AC Immune have collapsed after partner Genentech revealed its tau-targeting Alzheimer’s drug semorinemab had flunked a phase 2 trial in Alzheimer’s disease (AD). The post AC Immune poleaxed on Alzheimer’s study fail appeared first on.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Overcoming challenges in biosimilar analytical characterization

Drug Patent Watch

Additionally, the immunogenicity of biosimilars, which is the ability of the drug to trigger an immune response, can be highly variable and impact the safety and efficacy of the drug. 2016, November 11). Overcoming Regulatory Hurdles in the Development of Biosimilars. link] KBDNA. 2024, May 17). link] Lawless, L. link] Kurki, P.,

article thumbnail

German biotech CatalYm raises €50 million for GDF-15 inhibitor immunotherapy

pharmaphorum

Founded in 2016 as a spin-out from Wuerzburg University, CatalYm’s lead molecule CTL-002 is designed to neutralise the tumour-produced protein GDF-15. High concentrations of the GDF-15 in serum and tumour-micro-environment help cancers to evade the immune system and are associated with resistance to current therapies.

Immunity 105
article thumbnail

Early data back J&J and AC Immune’s Alzheimer’s jab

pharmaphorum

Shares in Swiss biotech AC Immune have risen sharply after it said a vaccine in development for Alzheimer’s disease (AD) hit the mark in a phase 1/2 trial. . The vaccine stimulated antibodies against the protein in all 32 patients with early-stage AD in the study at levels that AC Immune thinks should have a therapeutic effect.

Immunity 128
article thumbnail

Indian Immunologicals gets regulatory approval for measles-rubella (MR) vaccine

Express Pharma

This Live Attenuated MR vaccine adds to the list of several other vaccines that IIL supplies to Universal Immunization Programme (UIP) of India. IIL’s collaborative effort will help in the immunization of several million children against Measles and Rubella and thereby saving lives”.

article thumbnail

Intratumoural viral delivery improves glioblastoma survival

European Pharmaceutical Review

The viral therapy “aims to awaken the patient’s immune system and trigger a healing from within,” Dr Fueyo commented. After injection, patients that respond well develop inflammation inside the tumour, triggering an immune response that first kills the virus.” This makes it difficult to treat the cancer with immunotherapy.